These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11683006)

  • 21. Complications & side effects. Can statins be used as anti-HIV drugs?
    TreatmentUpdate; 2004; 16(7):9. PubMed ID: 17219689
    [No Abstract]   [Full Text] [Related]  

  • 22. Gender difference in viral load.
    Proj Inf Perspect; 1999 Apr; (27):18-9. PubMed ID: 11366734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The next big challenge: managing HIV infection in an age of higher resistance.
    AIDS Alert; 2001 Dec; 16(12):153, 155-7. PubMed ID: 11768873
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-HIV agents. A warning about high viral loads.
    TreatmentUpdate; 2003; 15(7):1-2. PubMed ID: 17216865
    [No Abstract]   [Full Text] [Related]  

  • 25. Interleukin-2: trials and tribulations.
    Kuritzkes DR
    J Infect Dis; 2009 Jul; 200(2):164-5. PubMed ID: 19508158
    [No Abstract]   [Full Text] [Related]  

  • 26. Who gets treatment and...side effects.
    TreatmentUpdate; 2002 Dec; 14(9):2-3. PubMed ID: 12593382
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV-1 tropism, disease progression, and clinical management.
    Burger H; Hoover D
    J Infect Dis; 2008 Oct; 198(8):1095-7. PubMed ID: 18783314
    [No Abstract]   [Full Text] [Related]  

  • 28. The current status of antiretroviral therapy in Africa.
    Bray DH
    J HIV Ther; 2006 Mar; 11(1):7-10. PubMed ID: 16706249
    [No Abstract]   [Full Text] [Related]  

  • 29. 2006 IAPAC state of HIV treatment surveys. Comprehensive insights into the mindsets of HIV-positive patients and HIV-treating physicians.
    IAPAC Mon; 2006 May; 12(5):150-5. PubMed ID: 17249141
    [No Abstract]   [Full Text] [Related]  

  • 30. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV/AIDS. Experts question danger of 'AIDS superbug'.
    Cohen J
    Science; 2005 Feb; 307(5713):1185. PubMed ID: 15731415
    [No Abstract]   [Full Text] [Related]  

  • 32. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB.
    TreatmentUpdate; 2004; 16(3):4-5. PubMed ID: 17219607
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical study on treatment of HIV infected persons based on viral load detection and CD4+ T lymphocyte counting].
    Lin X; Xu L; Feng Y; Li J; Pei L; Shen T; Shao Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Sep; 16(3):211-4. PubMed ID: 12665921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gender difference demonstrated in HIV viral load: researchers call for new treatment guidelines.
    J Gend Specif Med; 2000; 3(6):12. PubMed ID: 11253373
    [No Abstract]   [Full Text] [Related]  

  • 36. [HIV-infection: modern antiretroviral therapy].
    Rockstroh JK; Spengler U
    Dtsch Med Wochenschr; 2004 Sep; 129(37):1921-4. PubMed ID: 15372371
    [No Abstract]   [Full Text] [Related]  

  • 37. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
    Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
    J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The switching spiral: a triumph of hope over benefit?
    Moyle G
    AIDS Read; 2002 Apr; 12(4):147-50. PubMed ID: 12071184
    [No Abstract]   [Full Text] [Related]  

  • 39. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.